Drug Profile
LY 307599
Latest Information Update: 08 Jun 2001
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 08 Jun 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 07 Feb 1996 New profile
- 07 Feb 1996 Preclinical development for Bacterial infections in USA (Unknown route)